Serum apolipoprotein B (APOB) demonstrated an independent protective association with atrial fibrillation in both genders after adjusting for confounding factors (OR 0.121).
Case-Control (n=1,913)
No
Are serum apolipoprotein B levels associated with the presence of atrial fibrillation in hospitalized patients?
Lower serum apolipoprotein B levels are independently associated with the presence of atrial fibrillation, suggesting a potential biomarker role and adding to the evidence of a 'cholesterol paradox' in AF.
Effect estimate: OR 0.121 (95% CI 0.067-0.220)
Absolute Event Rate: 0.8% vs 0.99%
p-value: p=<0.001
The relationship between apolipoprotein B (APOB) and atrial fibrillation (AF) is less well-known. We aimed to investigate the association between APOB and AF by gender. We conducted a case-control study including 1913 consecutive hospitalized patients to analyze the association between APOB and AF. 950 AF patients and 963 age-, sex-matched non-AF patients with sinus rhythm were evaluated. T-test, Mann-Whitney test, ANOVA, and Chi-square analysis were performed to analyze baseline data and intergroup comparisons. Pearson's correlation tests or Spearman correlation tests were performed to determine the interrelationships. Multiple regression analysis was performed to adjust for covariables. The receiver operator characteristic (ROC) curve was constructed to examine the performance of APOB. AF patients had lower APOB (P < 0.001) and an independent negative association between APOB and AF in both genders adjusting for confounding factors (OR 0.121, 95% CI 0.067-0.220, P < 0.001), regardless of statin use. APOB was positively correlated with total cholesterol (TC) (r = 0.529, p < 0.001), low-density lipoprotein cholesterol (LDL-C) (r = 0.545, p < 0.001), apolipoprotein A1 (APOA1) (r = 0.083, p < 0.001), and albumin (ALB) (r = 0.134, p < 0.001). ROC curve analysis showed that APOB level = 0.895 g/L was the most optimal cut-off value, the area under the ROC curve was 0.722. This study shows a protective association of APOB with AF in men and women. It implies APOB may be a potential biomarker for AF with a promising cut-off point of 0.895 g/L and may involve initiating and maintaining AF along with several metabolic factors.
Zhong et al. (2022) conducted a case-control in Atrial fibrillation (n=1,913). Serum apolipoprotein B (APOB) vs. Non-AF patients with sinus rhythm was evaluated on Association between serum APOB and atrial fibrillation (adjusted for all confounding factors) (OR 0.121, 95% CI 0.067-0.220, p=<0.001). Serum apolipoprotein B (APOB) demonstrated an independent protective association with atrial fibrillation in both genders after adjusting for confounding factors (OR 0.121).